IN THE CLAIMS

This listing of claims replaces all prior versions, and listings, in this application.

1. (currently amended) A method of inducing an adaptive immune response in a patient to a target antigen comprising administering to said patient a flagellin protein[[,]] or [[a]] peptide fragment thereof[[,]] as claimed in Claim 12 in an amount effective to induce said response.

2. (currently amended) A method according to claim 1 wherein the flagellin protein or peptide fragment thereof is capable of directly inducing the dendritic cell adaptive immune response.

3. (previously presented) A method according to claim 1 wherein dendritic cell maturation is increased.

4. (currently amended) A method according to claim 1 wherein the flagellin protein or peptide fragment thereof is administered via a [[the]] mucosal route.

5. (currently amended) A method according to claim 1 wherein the flagellin protein or peptide fragment thereof is administered orally or intranasally.

6. (previously presented) A method according to claim 1 wherein the flagellin protein includes at least one of the conserved regions of the N terminal sequence and the C terminal sequence of flagellin.

7. (previously presented) A method according to claim 1 wherein the flagellin protein includes at least one of the conserved regions of residues 1-190 and 354-494 of *S. typhimurium* as shown underlined in Figure 8 herein.

8. (currently amended) A method as claimed in claim 1 wherein the flagellin protein or peptide fragment thereof and the target antigen are co-administered.

9. (currently amended) A method of manufacturing ~~Use of a flagellin protein or peptide fragment thereof in the manufacture of~~ a medicament for [[the]] induction of an adaptive immune response comprising combining a flagellin protein or peptide fragment thereof as claimed in Claim 12 with a pharmaceutically acceptable carrier, excipient or diluent in sterile pyrogen free form.

10. (currently amended) A method according to claim 9 wherein ~~Use as claimed in Claim 9 characterised in that~~ the medicament induces ~~is for inducing~~ recruitment of immature dendritic cells in mucosal vaccination such as to induce an adaptive immune response.

11. (currently amended) A method according to claim 9 wherein ~~Use as claimed in Claim 9 characterised in that~~ the medicament is an adjuvant.

12. (currently amended) A flagellin protein or peptide fragment thereof for use in therapy wherein ~~characterised in that~~ the flagellin protein or peptide fragment thereof is truncated, mutated or has deletions therein which allow it to retain its ability to induce the immune response.

13. (currently amended) A flagellin protein or peptide fragment thereof as claimed in Claim 12 which ~~characterised in that it retains the ability to~~ binds to intestinal or epithelial cell flagellin receptors and has ~~retain~~ immune signalling properties after the truncation, mutation or deletion.

14. (currently amended) A flagellin protein or peptide fragment thereof as claimed in Claim 12 wherein ~~characterised in that~~ the flagellin protein includes at least one of the conserved regions of residues 1-190 and 354-494 of *S. typhimurium* as shown underlined in Figure 8 herein.

15. (previously presented) An adjuvant composition comprising a flagellin protein or peptide fragment thereof as claimed in Claim 12 together with a pharmaceutically acceptable carrier, excipient or diluent in sterile pyrogen free form.

16. (original) A vaccine composition comprising an adjuvant composition as claimed in claim 15 and a target antigen.

17. (new) A flagellin protein or peptide fragment thereof as claimed in Claim 12 wherein the flagellin protein includes at least one of the conserved regions of the N terminal sequence and the C terminal sequence of flagellin.

18. (new) A method according to claim 9 wherein the medicament further comprises a target antigen.